Thomas Daniel Net Worth

The estimated Net Worth of Thomas O Daniel is at least $53.1 Thousand dollars as of 16 December 2015. Thomas Daniel owns over 7,500 units of Zafgen stock worth over $53,074 and over the last 8 years he sold ZFGN stock worth over $0. In addition, he makes $0 as Director at Zafgen.

Thomas Daniel ZFGN stock SEC Form 4 insider trading

Thomas has made over 26 trades of the Zafgen stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of ZFGN stock worth $5,713 on 16 December 2015.

The largest trade he’s ever made was exercising 36,366 units of Zafgen stock on 27 July 2015 worth over $1,082,616. On average, Thomas trades about 7,608 units every 12 days since 2012. As of 16 December 2015 he still owns at least 69,678 units of Zafgen stock.

You can see the complete history of Thomas Daniel stock trades at the bottom of the page.

Thomas Daniel biography

Dr. Thomas O. Daniel serves as Director of the company. Prior to joining Celgene, Dr. Daniel served as Chief Scientific Officer and Director of AmbRx Inc., and as Vice President, Research at Amgen Inc. Prior to Amgen’s acquisition of Immunex, Dr. Daniel was Senior Vice President of Discovery Research at Immunex. He currently is a director of Juno Therapeutics. Dr. Daniel serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center and is a member of the Therapeutic Advisory Board of aTyr Pharma, Inc. He also serves as co-chairman of the Biomedical Advisory Committee of PhRMA. Dr. Daniel, a nephrologist and former academic investigator, was previously the Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. He conducted research supported by the National Institutes of Health and the Howard Hughes Medical Institute at UC San Francisco. He earned his M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital.

How old is Thomas Daniel?

Thomas Daniel is 65, he’s been the Director of Zafgen since 2016. There are 3 older and 6 younger executives at Zafgen. The oldest executive at Zafgen, Inc. is Wendy Everett, 72, who is the Director.

What’s Thomas Daniel’s mailing address?

Thomas’s mailing address filed with the SEC is C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT, NJ, 07901.

Insider trading at Zafgen

Over the last 5 years, insiders at Zafgen have traded over $14,218,922 worth of Zafgen stock and bought 689,531 units worth $3,998,442 . The most active insider traders include James E Deerfield Mgmt L.P…., Kevin P Starr, and James E Deerfield Mgmt L.P….. On average, Zafgen executives and independent directors trade stock every 53 days with the average trade being worth of $67,334. The most recent stock trade was executed by Thomas E. Hughes on 28 June 2018, trading 32,000 units of ZFGN stock currently worth $320,000.

What does Zafgen do?

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

What does Zafgen’s logo look like?

Complete history of Thomas Daniel stock trades at Celgene, Zafgen, and Magenta Therapeutics

Zafgen executives and stock owners

Zafgen executives and other stock owners filed with the SEC include:

  • Frank Thomas, Independent Director
  • John LaMattina, Independent Director
  • Robert Perez, Director
  • Geoffrey McDonough, Director
  • Wendy Everett, Director
  • Thomas Daniel, Director
  • Priya Singhal, Head of Research and Development
  • Brian McVeigh, Chief Business Officer
  • Patricia Allen, Chief Financial Officer
  • Jeffrey Hatfield, Chief Executive Officer, Director
  • Peter Barrett, Independent Chairman of the Board
  • Patrick Loustau, President
  • Frances K Heller, Director
  • Dennis D Kim, Chief Medical Officer
  • Alicia Secor, Chief Commercial Officer
  • James E Deerfield Mgmt L.P….,
  • Bruce Booth, Director
  • James E Deerfield Mgmt L.P….,
  • Venture Fund Vii L P Atlas …,
  • Avi Y. Goldberg, Director
  • Rock Ventures Lp Third Rock…,
  • Rock Ventures Lp Third Rock…,
  • Thomas E. Hughes, Chief Executive Officer
  • Kevin P Starr, Director